Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05678621
Other study ID # TRU-RLS-21
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date November 30, 2022
Est. completion date April 2027

Study information

Verified date April 2024
Source Monash University
Contact Prof Zoe McQuilten
Phone +61 3 9903 0379
Email zoe.mcquilten@monash.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to find out if patients with blood cancers receiving immunoglobulin (Ig) for the purpose of preventing infections can safety stop immunoglobulin after six months of therapy, and take oral antibiotics instead to prevent serious infections. Patients may be eligible to join this study if they are aged 18 years or above, have an acquired hypogammaglobulinaemia secondary to a haematological malignancy, and have been receiving intravenous or subcutaneous Ig for longer than 6 consecutive months. Participants will be randomised (allocated by chance) to one of three treatment groups, as follows: - Stop immunoglobulin (IVIg or SCIg) and be given oral antibiotics to take every day (ARM A) - Stop immunoglobulin (IVIg or SCIg) and be given oral antibiotics to keep at home to use as soon as symptoms of an infection develop (ARM B) - Continue receiving immunoglobulin (IVIg or SCIg) - this is the usual care group (ARM C) The duration of each treatment is for 12 months from study entry. Participants will be asked to attend a screening/baseline visit so that their treating clinician can assess their eligibility for the trial and collect baseline data. If eligible for the trial, participants will then be randomly allocated to one of the three treatment groups. Once randomised, active participation in the study will last for 13 months. During this period, participants will be asked to return to the hospital for a study visit every 3 months, with monthly telephone visits to check-in on your progress between each in-person visit. Participants will also be asked to complete a study diary, recording treatment compliance and signs/symptoms of infection experienced throughout the study period. Types of assessments and data collected will include: Medical history, demographics, physical examination, blood tests, stool sample, quality of life questionnaires, information about your general health, hospitalisations, medications and procedures. In order to assess and compare the cost-effectiveness of the treatment groups, the study team will also request authorisation from participants to access their Medicare Benefits Schedule (MBS), Pharmaceutical Benefits Scheme (PBS), and Australian Immunisation Register (AIR) data.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date April 2027
Est. primary completion date April 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Aged greater than or equal to 18 years of age 2. Diagnosis of chronic lymphocytic leukaemia (CLL), multiple myeloma (MM) or non-Hodgkin lymphoma (NHL). 3. Patients must be receiving Ig (IV or subcutaneous - SCIg) replacement for prevention of bacterial infections due to hypogammaglobulinaemia for longer than 6 consecutive months. 4. Patient is eligible for trial of Ig cessation in the opinion of the treating clinician and local investigator. 5. Life expectancy greater than 12 months. 6. Able to give informed consent, and willing and able to comply with each of the treatment arms. Exclusion Criteria: 1. Prior or planned allogeneic haematopoietic stem cell transplantation. 2. Major infection (Grade 3 or higher) in preceding 3 months, and/or current active infection requiring antimicrobial treatment. 3. Already receiving daily antibiotic prophylaxis for the purpose of preventing bacterial infection (Note: patients may receive antiviral, antifungal and Pneumocystis jirovecii pneumonia (PJP) prophylaxis). 4. Intolerance of all trial antibiotic options in either arm A or arm B. 5. Communication, compliance or logistical issues that are likely to limit patient's ability to take prophylactic or emergency antibiotics, or to obtain urgent medical attention for symptoms of infection. 6. Pregnant or breastfeeding. 7. Severe renal impairment (estimated or measured creatinine clearance of less than 30 mL/min). 8. Previous splenectomy. 9. Previous participation in this trial. 10. Treating team deems enrolment in the study is not in the best interests of the patient.

Study Design


Intervention

Drug:
trimethoprim-sulfamethoxazole (co-trimoxazole)
Doxycycline is an alternative for participants with hypersensitivity to co-trimoxazole.
amoxycillin/clavulanic acid and ciprofloxacin
clindamycin is an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.
Immunoglobulins
Intravenous monthly immunoglobulin or subcutaneous weekly immunoglobulin

Locations

Country Name City State
Australia Monash Medical Centre Clayton Victoria
Australia Concord Hospital Concord New South Wales
Australia Canberra Hospital Garran Australian Capital Territory
Australia Austin Hospital Heidelberg Victoria
Australia The Alfred Hospital Melbourne Victoria
Australia Sunshine Hospital St Albans Victoria
Australia Royal North Shore St Leonards New South Wales

Sponsors (1)

Lead Sponsor Collaborator
Monash University

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Event-free survival (EFS), defined as time from randomisation until occurrence of a Grade 3 or higher infection (as defined by CTCAE Version 5), or death from any cause. 12 months following randomisation
Secondary Proportion of patients who develop at least 1 Grade 3 or higher infection(s) from randomisation to 12 months. 12 months following randomisation
Secondary Proportion of patients with one or more clinically documented infections (symptoms/signs of infection requiring antimicrobial treatment) to 12 months. 12 months following randomisation
Secondary Number of clinically documented infections (symptoms/signs of infection requiring antimicrobial treatment) to 12 months. Data collected from medical records will inform this outcome measure. 12 months following randomisation
Secondary Proportion of patients with one or more microbiologically documented bacterial infections. 12 months following randomisation
Secondary Number of microbiologically documented bacterial infections. 12 months following randomisation
Secondary Time free from hospitalisation and antimicrobials with therapeutic intent. 12 months following randomisation
Secondary Proportion of patients with one or more treatment-related adverse events 12 months following randomisation
Secondary Number of treatment-related adverse events. 12 months following randomisation
Secondary Proportion of patients with fluoroquinolone resistant organisms, co-trimoxazole resistant organisms, extended spectrum beta lactamases or multidrug resistant organisms isolated. 12 months following randomisation
Secondary Number of infections with fluoroquinolone resistant organisms, co-trimoxazole resistant organisms, extended spectrum beta lactamases or multidrug resistant organisms isolated. 12 months following randomisation
Secondary Quality of Life (QoL) measured at randomisation then 3, 6, 9 and 12 months QoL will be assessed using the EORTC QLQ-C30 questionnaire. Randomisation and 3, 6, 9 and 12 months following randomisation.
Secondary Quality of Life (QoL) measured at randomisation then 3, 6, 9 and 12 months QoL will be assessed using the Functional Assessment of Cancer Therapy - Neutropenia (FACT-N) questionnaire. Randomisation and 3, 6, 9 and 12 months following randomisation.
Secondary Quality of Life (QoL) measured at randomisation then 3, 6, 9 and 12 months QoL will be assessed using the EQ-5D-5L questionnaire. Randomisation and 3, 6, 9 and 12 months following randomisation.
Secondary Costs associated with allocated treatment arm and infections during study Costs associated with each treatment arm with be aggregated into Australian dollars. Aggregate costs will be calculated based on the following data sources: medical records, infection-related hospitalisations (using unit costs based on unlinked data from the Victorian Admitted Episodes Dataset, Victorian Emergency Minimum Dataset and the Victorian Cost Data Collection), Medicare Benefits Scheme (MBS), Pharmaceutical Benefits Scheme (PBS) and Australian Immunisation Registry (AIR) data. 12 months following randomisation
Secondary Cost effectiveness of the allocated treatment arm Differences in costs and Quality Adjusted Life Years (QALYs) for each of the treatment arms will be aggregated into a cost effectiveness ratio. The following data sources will be used to calculate this outcome measure: the EORTC QLQ-C30 questionnaire will be used to calculate QALYS. Costs will be calculated based on the following data sources: medical records, infection-related hospitalisations (using unit costs based on unlinked data from the Victorian Admitted Episodes Dataset, Victorian Emergency Minimum Dataset and the Victorian Cost Data Collection), Medicare Benefits Scheme (MBS), Pharmaceutical Benefits Scheme (PBS) and Australian Immunisation Registry (AIR) data. 12 months following randomisation
Secondary Trough IgG level at 3, 6, 9 and 12 months from baseline. 3, 6, 9 and 12 months from baseline
Secondary Proportion of patients in immunoglobulin cessation treatment arms who restart Ig over 12 months. 12 months following randomisation
Secondary Covid anti-spike protein levels at baseline, 3, 6, 9, and 12 months. 3, 6, 9 and 12 months following baseline
See also
  Status Clinical Trial Phase
Terminated NCT03978312 - Nutrition Health Literacy of Cancer Patients and Their Support Networks.
Recruiting NCT03750994 - Economic Evaluation of Innovative Molecular Analyses in Onco-haematology
Recruiting NCT04397705 - Remote Monitoring of Cancer Patients With Suspected Covid-19 Phase 1
Recruiting NCT05203809 - Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignancies
Active, not recruiting NCT03146468 - Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation Phase 2
Recruiting NCT05298930 - Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation N/A
Not yet recruiting NCT06395220 - Kinectics of Donor-specific Anti-HLA Antibody After HLA-incompatible Allogeneic Haematopoietic Stem Cell Transplantation
Recruiting NCT05786716 - DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations Phase 2/Phase 3
Not yet recruiting NCT04673305 - Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies N/A
Recruiting NCT05722886 - DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol Phase 2/Phase 3
Recruiting NCT05768178 - DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Phase 2/Phase 3
Completed NCT03855969 - Central Venous Access Device Removal in Cancer Patients
Recruiting NCT04174053 - Concordance Between 2 Means of Temperature Measure in Neutropenic Patients Hospitalized in Intensive Hematology Care Units N/A
Recruiting NCT05770544 - DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. Phase 2/Phase 3
Recruiting NCT05379738 - Impact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy N/A
Completed NCT04236063 - Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Recruiting NCT05695638 - Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
Recruiting NCT04298892 - Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies
Withdrawn NCT03688789 - Hématologie Adulte Prevalence of Adrenal Insufficiency Post-chemotherapy Adrenocorticotropia in Adult Hematology N/A
Withdrawn NCT04331483 - A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts N/A